Back

Mavacamten reduces left ventricular mechanical dispersion in hypertrophic obstructive cardiomyopathy

11 December 2024 (00:00 - 16:00)
Organised by: Logo
Congress Presentation Part of: Imaging of the hypertrophied left ventricle Myocardial Disease EACVI Premium Access EuroEcho-Imaging 2024 European Association of Cardiovascular Imaging (EACVI)

About the speaker

Photo
Doctor Benay Ozbay

Upmc University Of Pittsburgh Medical Center, Pittsburgh (United States of America)

4 More presentations in this session

Presentation thumbnail
Right atrial strain in Anderson-Fabry disease
Doctor R. Lillo (Rome, IT)
Abstract Slides
Presentation thumbnail
Abnormal right ventricular strain predicts poor prognosis in transthyretin amyloidosis
Doctor S. Istratoaie (Cluj Napoca, RO)
Abstract Slides
Presentation thumbnail
Differential diagnosis of hypertrophic cardiomyopathy, fabry cardiomyopathy and transthyretin cardiac amyloidosis: insights from right ventricular strain imaging echocardiography
Doctor E. Mata (Creixomil, PT)
Abstract Slides
Presentation thumbnail
The cardiac myosin inhibitor mavacamten reduces even extreme left ventricular outflow gradient in obstructive hypertrophic cardiomyopathy already after one week of treatment
Doctor V. Nagy (Szeged, HU)
Abstract Slides

Access the full session

Session thumbnail
Imaging of the hypertrophied left ventricle

The Event

Event poster

EuroEcho-Imaging 2024

11 December - 13 December 2024
You may be interested in
thumbnail
Congress Presentation
Echocardiography as first-line technique in suspected cardiac amyloidosis
thumbnail
Congress Presentation
What is the best imaging method to assess myocardial viability? 
thumbnail
Congress Presentation
Dilated cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources